CJC-1295 is a synthetic peptide studied in laboratory and clinical-research settings as a long-acting analog of growth hormone–releasing hormone (GHRH) [doi:10.1016/j.ghir.2009.03.001]. It belongs to a broader class of GHRH-related research peptides that investigators examine when characterizing the regulation of the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) signaling axis. Within the supply chain for laboratory work, CJC-1295 is classified strictly as a Research Use Only (RUO) compound and is not designed, approved, or cleared for administration in any living subject.
Researchers study CJC-1295 primarily because it offers a stable, extended-duration probe for the GH/IGF-1 axis, allowing investigation of GHRH-receptor signaling, downstream biomarker changes, and the pharmacology of peptide therapeutics more generally [doi:10.1016/j.ghir.2009.03.001] [PMID: 41966639]. The following overview summarizes the published mechanism, key findings, and biochemical characteristics of CJC-1295 in a research context.
Mechanism of Action
CJC-1295 functions as a GHRH analog. Native GHRH is a hypothalamic polypeptide that binds receptors on pituitary somatotropes to promote the release of growth hormone [doi:10.1016/j.ghir.2009.03.001]. By acting at this same receptor target, CJC-1295 has been reported in published research to activate the GH/IGF-1 axis in normal adult subjects, with measurable downstream effects on circulating biomarkers [doi:10.1016/j.ghir.2009.03.001].
In the study by Sackmann-Sala and colleagues, CJC-1295 administration was associated with activation of the GH/IGF-1 axis and with changes in the serum protein profile of normal adult subjects, an observation the authors used to explore new markers of GH activity [doi:10.1016/j.ghir.2009.03.001]. The defining mechanistic feature highlighted in the literature is its long-acting profile relative to native GHRH, which extends the window over which GHRH-receptor signaling and its biomarker consequences can be observed [doi:10.1016/j.ghir.2009.03.001]. A broader narrative review of peptides in sports medicine likewise classifies CJC-1295 among GHRH-axis compounds and discusses its pharmacological mechanism alongside related agents [PMID: 41966639].
Research Overview
Published research on CJC-1295 is concentrated on its role as a tool for studying GH/IGF-1 axis activation. The 2009 work in normal adult subjects remains a primary reference, reporting serum protein profile changes consistent with GH and IGF-1 action following CJC-1295 administration [doi:10.1016/j.ghir.2009.03.001]. This positions CJC-1295 as one approach to identifying biomarkers of GH activity, an area of interest because conventional markers such as IGF-1, IGFBP-3, and collagen peptides show substantial population variability [doi:10.1016/j.ghir.2009.03.001].
A 2026 narrative review in Sports Medicine places CJC-1295 within a wider landscape of approved and unapproved peptides marketed in performance and recovery contexts, alongside compounds such as sermorelin, ipamorelin, tesamorelin (Egrifta), AOD-9604, BPC-157, MOTS-C, GHK-Cu (glycyl-L-histidyl-L-lysine copper), and TB-500 (thymosin beta-4 fragment) [PMID: 41966639]. The authors note that many unapproved peptides demonstrate favorable outcomes in animal models, but emphasize that rigorous human safety data are scarce and that regulatory status varies widely across this class [PMID: 41966639]. Researchers exploring CJC-1295 frequently cross-reference these related research peptides — for example MOTS-C, GHK-Cu, and TB-500 — when designing comparative or mechanistic studies [PMID: 41966639]. This review is a useful entry point for understanding where CJC-1295 sits relative to both approved analogs and gray-market compounds.
Compound Characteristics
CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone, characterized in the literature by its extended duration of action compared with native GHRH [doi:10.1016/j.ghir.2009.03.001]. As a short-chain amino acid construct, it occupies the pharmacological niche between small-molecule drugs and large proteins that defines the peptide class as a whole [PMID: 41966639]. Its long-acting property is the biochemical feature most consistently emphasized in published work, distinguishing it from shorter-lived GHRH fragments and supporting its use as a stable research probe of GHRH-receptor signaling [doi:10.1016/j.ghir.2009.03.001].
For laboratory handling, CJC-1295 is treated as a research-grade lyophilized peptide. As with other peptides in this category, stability and integrity depend on appropriate storage and reconstitution practices in the laboratory setting. All characterization here is presented for research documentation only and does not constitute guidance for any in-life application.
CJC-1295 vs Related Compounds
The table below compares CJC-1295 with two related GHRH-axis research peptides referenced in the cited literature. All entries are framed for research-classification purposes only.
| Feature | CJC-1295 | Sermorelin | Tesamorelin |
|---|---|---|---|
| Compound class | Synthetic GHRH analog [doi:10.1016/j.ghir.2009.03.001] | GHRH-related peptide [PMID: 41966639] | GHRH analog (Egrifta) [PMID: 41966639] |
| Molecular target | Pituitary somatotrope GHRH receptor [doi:10.1016/j.ghir.2009.03.001] | GHRH-receptor axis [PMID: 41966639] | GHRH-receptor axis [PMID: 41966639] |
| Mechanistic focus | GH/IGF-1 axis activation [doi:10.1016/j.ghir.2009.03.001] | GH/IGF-1 axis signaling [PMID: 41966639] | GH/IGF-1 axis signaling [PMID: 41966639] |
| Duration profile | Long-acting relative to native GHRH [doi:10.1016/j.ghir.2009.03.001] | Reviewed as a GHRH-axis comparator [PMID: 41966639] | Reviewed as a GHRH-axis comparator [PMID: 41966639] |
| Regulatory status in cited review | Listed among unapproved peptides [PMID: 41966639] | Reviewed alongside CJC-1295 [PMID: 41966639] | Named among approved peptides [PMID: 41966639] |
| Research context | Biomarker / GH-activity studies [doi:10.1016/j.ghir.2009.03.001] | Sports-medicine peptide review [PMID: 41966639] | Sports-medicine peptide review [PMID: 41966639] |
This comparison is intended to orient researchers among GHRH-axis compounds and is not a statement of equivalence or interchangeability.
Research Availability
CJC-1295 is offered for research use through laboratory peptide suppliers that serve academic, institutional, and independent research settings. Stackhaus Research supplies CJC-1295 as a Research Use Only compound for in vitro and laboratory investigation. Researchers sourcing CJC-1295 should confirm research-grade documentation and handle the material according to standard laboratory practice. No CJC-1295 product from Stackhaus Research is approved for administration, ingestion, or any in-life application.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) studied as a long-acting probe of the GH/IGF-1 axis [doi:10.1016/j.ghir.2009.03.001]. It is classified strictly as a Research Use Only compound. Published research has examined its activation of GH and IGF-1 signaling in normal adult subjects [doi:10.1016/j.ghir.2009.03.001].
How does CJC-1295 work at the molecular level?
CJC-1295 acts as a GHRH analog at the GHRH receptor on pituitary somatotropes, the same target through which native GHRH promotes growth hormone release [doi:10.1016/j.ghir.2009.03.001]. In published research it has been associated with activation of the GH/IGF-1 axis and measurable serum protein profile changes [doi:10.1016/j.ghir.2009.03.001].
How does CJC-1295 relate to other research peptides?
A 2026 narrative review groups CJC-1295 with other GHRH-axis and peptide-class compounds, including sermorelin, ipamorelin, and tesamorelin, as well as distinct peptides such as MOTS-C, GHK-Cu, and TB-500 [PMID: 41966639]. Researchers often reference these related compounds when designing comparative studies. The review also notes that human safety data across many of these peptides remain limited [PMID: 41966639].
What makes CJC-1295 of interest to researchers?
Its long-acting profile relative to native GHRH makes CJC-1295 a stable tool for studying GHRH-receptor signaling and biomarkers of GH activity [doi:10.1016/j.ghir.2009.03.001]. This is relevant because conventional GH-activity markers show high population variability [doi:10.1016/j.ghir.2009.03.001].
Where can researchers source CJC-1295?
CJC-1295 is available for laboratory research through peptide suppliers, including Stackhaus Research, which provides it as a Research Use Only compound. Researchers should verify research-grade documentation and follow appropriate laboratory storage and handling practices. It is not approved for any in-life use or clinical administration of any kind.